Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gb Sciences Inc
(OP:
GBLX
)
0.0070
UNCHANGED
Streaming Delayed Price
Updated: 2:52 PM EDT, Aug 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
15,788
Open
0.0070
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0070
Today's Range
0.0068 - 0.0070
52wk Range
0.0050 - 0.0140
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
GB Sciences Signs Letter of Intent for a License to Develop and Market Their Cannabinoid-Based Parkinson’s Formulation With Endopure Life Sciences
July 02, 2024
Via
ACCESSWIRE
Gb Sciences’ Novel Parkinson’s Disease Medication is Featured on Worldwide Business with kathy ireland(R)
December 14, 2023
Via
ACCESSWIRE
Performance
YTD
+9.37%
+9.37%
1 Month
-19.54%
-19.54%
3 Month
+2.94%
+2.94%
6 Month
+25.00%
+25.00%
1 Year
-19.54%
-19.54%
More News
Read More
Gb Sciences' First-in-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study at the University of Lethbridge
July 11, 2023
Via
ACCESSWIRE
GB Sciences' First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease Has Been Issued in China
March 20, 2023
Via
ACCESSWIRE
Successful 2022 Milestones Support Value of Gb Sciences' AI-Enabled Drug Discovery Platform
March 07, 2023
Via
ACCESSWIRE
Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform
December 22, 2022
Via
Newswire.com
Topics
Death
Exposures
COVID-19
Death
Marijuana And Chronic Pain: Gb Sciences' Nanoparticle Technology Boosts Efficacy Of Cannabis Terpenes
March 29, 2022
Via
Benzinga
Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform
December 22, 2022
From
Gb Sciences
Via
GlobeNewswire
Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations
December 12, 2022
Via
Newswire.com
Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations
December 12, 2022
From
Gb Sciences
Via
GlobeNewswire
Cannabis Terpenes Reduce Inflammation, Says Gb Sciences Study
November 01, 2022
Via
Benzinga
Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients
November 01, 2022
Via
Newswire.com
Topics
Cannabis
Exposures
Cannabis
Gb Sciences' Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study
October 24, 2022
Via
Newswire.com
TODAY: Gb Sciences' President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 Conference
October 13, 2022
Via
Newswire.com
Topics
Cannabis
Exposures
Cannabis
New Study Shows Promising Results In Treatment Of Parkinson's Disease With Cannabinoids
October 10, 2022
Via
Benzinga
Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease
October 10, 2022
Via
Newswire.com
Topics
Cannabis
Exposures
Cannabis
TODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article
September 06, 2022
Via
Newswire.com
Topics
Cannabis
Exposures
Cannabis
TODAY: Gb Sciences' President and Chief Science Officer Presents Keynote Address on Cannabinoid-Containing Formulations for Parkinson's Disease at 2022 NeuroForum Summit
May 23, 2022
Via
Newswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
TODAY: Gb Sciences Showcases Its PhAROS™ Drug Discovery Platform at the 2nd ALCOR Drug Discovery Platform Summit
May 12, 2022
Via
Newswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
TODAY: Gb Sciences' Novel Plant-Inspired Pain Medications Featured at SMi's 22nd Annual Pain Therapeutics Conference
May 05, 2022
Via
Newswire.com
FHI Clinical to Write Clinical Trial Protocol for Development of Gb Sciences' COVID-19-Related, Anti-Inflammatory Therapies
May 02, 2022
Via
Newswire.com
Exposures
COVID-19
Gb Sciences To Begin Dosage Study For Cannabinoid-Containing Drug For Treatment Of Parkinson's Disease
April 12, 2022
Via
Benzinga
Gb Sciences to Begin Dosage Study for Its Novel Parkinson's Disease Formulations at the University of Lethbridge
April 12, 2022
Via
Newswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Our Chronic Pain Formulations as Demonstrated in New Research Article
March 29, 2022
Via
Newswire.com
UPDATE: Gb Sciences Issues Shareholder Letter
March 16, 2022
Via
Newswire.com
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.